Bioventus (NYSE:BVS) Sets New 52-Week High at $10.53

Bioventus Inc. (NYSE:BVS) reached a new 52-week high during trading on Tuesday . The company traded as high as $10.53 and last traded at $10.36, with a volume of 41994 shares traded. The stock had previously closed at $10.50.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on BVS shares. Canaccord Genuity Group boosted their target price on shares of Bioventus from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, August 13th. Craig Hallum upped their price target on shares of Bioventus from $9.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, August 7th.

Bioventus Stock Up 2.9 %

The stock has a market capitalization of $833.62 million, a price-to-earnings ratio of -30.09 and a beta of 0.88. The firm’s fifty day moving average is $8.06 and its 200-day moving average is $6.36. The company has a debt-to-equity ratio of 1.82, a current ratio of 1.33 and a quick ratio of 0.96.

Bioventus (NYSE:BVS) last released its earnings results on Tuesday, August 6th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.12. Bioventus had a negative net margin of 7.82% and a positive return on equity of 14.39%. The firm had revenue of $151.22 million during the quarter, compared to analyst estimates of $137.70 million. During the same quarter in the previous year, the firm earned $0.14 earnings per share. On average, sell-side analysts predict that Bioventus Inc. will post 0.4 earnings per share for the current year.

Insider Buying and Selling at Bioventus

In other Bioventus news, Director John A. Bartholdson bought 25,500 shares of the stock in a transaction on Monday, August 19th. The stock was purchased at an average price of $8.55 per share, for a total transaction of $218,025.00. Following the completion of the purchase, the director now directly owns 6,939,357 shares in the company, valued at $59,331,502.35. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Bioventus news, Director John A. Bartholdson bought 25,500 shares of the stock in a transaction on Monday, August 19th. The stock was purchased at an average price of $8.55 per share, for a total transaction of $218,025.00. Following the completion of the purchase, the director now directly owns 6,939,357 shares in the company, valued at $59,331,502.35. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Mark Leonard Singleton sold 13,753 shares of the business’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $5.84, for a total transaction of $80,317.52. Following the sale, the chief financial officer now owns 63,114 shares of the company’s stock, valued at approximately $368,585.76. The disclosure for this sale can be found here. Insiders sold a total of 40,184 shares of company stock worth $230,591 over the last 90 days. Insiders own 32.90% of the company’s stock.

Hedge Funds Weigh In On Bioventus

Institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC bought a new position in shares of Bioventus during the first quarter worth about $28,000. Lazard Asset Management LLC bought a new position in shares of Bioventus during the first quarter worth about $40,000. HB Wealth Management LLC bought a new position in shares of Bioventus during the second quarter worth about $60,000. Burns Matteson Capital Management LLC bought a new position in Bioventus in the 2nd quarter valued at about $67,000. Finally, SG Americas Securities LLC bought a new position in Bioventus in the 1st quarter valued at about $66,000. Institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.